In the Spotlight
FDA grants orphan drug status to selumetinib for neurofibromatosis type 1 (NF1) treatment
The U.S. Food and Drug Administration granted orphan drug status in February to selumetinib for use in patients with the genetic disorder neurofibromatosis type 1 (NF1), who often develop tumors of the peripheral nervous system. Receiving orphan drug designation is a helpful step for selumetinib.
Read More